KRYS
What one share of Krystal Biotech holds
Biological Products, (No Diagnostic Substances)
We are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. Using our patented gene therapy technology platform that is based on engineered herpes simplex virus-1 (“HSV-1”), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems.
Krystal Biotech’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $14.52 |
|---|---|
| Profit | $7.96 |
| Capex (buildings and equipment) | $0.48 |
| Free cash flow | $8.50 |
| Cash and investments | $14.45 |
| Book value | $45.92 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$1.31 | $0.02 | −$1.51 | — | — |
| 2017 | — | −$1.48 | $0.04 | −$0.76 | — | $4.80 |
| 2018 | — | −$0.97 | $0.20 | −$1.04 | — | $7.85 |
| 2019 | — | −$1.20 | $0.40 | −$1.58 | — | $11.69 |
| 2020 | — | −$1.71 | $0.79 | −$2.18 | — | $14.82 |
| 2021 | $0.00 | −$3.13 | $3.08 | −$5.24 | — | $23.55 |
| 2022 | $0.00 | −$5.49 | $2.08 | −$6.02 | — | $20.27 |
| 2023 | $1.83 | $0.39 | $0.43 | −$3.63 | — | $27.58 |
| 2024 | $9.77 | $3.00 | $0.14 | $4.01 | — | $32.87 |
| 2025 | $12.99 | $6.84 | $0.40 | $6.31 | — | $41.78 |